198 related articles for article (PubMed ID: 22428569)
1. Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells.
Ramasamy K; Khatun H; Macpherson L; Caley MP; Sturge J; Mufti GJ; Schey SA; Calle Y
Br J Haematol; 2012 Jun; 157(5):564-79. PubMed ID: 22428569
[TBL] [Abstract][Full Text] [Related]
2. A method for measurement of drug sensitivity of myeloma cells co-cultured with bone marrow stromal cells.
Misund K; Baranowska KA; Holien T; Rampa C; Klein DC; Børset M; Waage A; Sundan A
J Biomol Screen; 2013 Jul; 18(6):637-46. PubMed ID: 23446700
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
Nefedova Y; Landowski TH; Dalton WS
Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386
[TBL] [Abstract][Full Text] [Related]
4. KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts.
Miki H; Ozaki S; Nakamura S; Oda A; Amou H; Ikegame A; Watanabe K; Hiasa M; Cui Q; Harada T; Fujii S; Nakano A; Kagawa K; Takeuchi K; Yata K; Sakai A; Abe M; Matsumoto T
Br J Haematol; 2011 Nov; 155(3):328-39. PubMed ID: 21902681
[TBL] [Abstract][Full Text] [Related]
5. Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma.
de Queiroz Crusoe E; Maiso P; Fernandez-Lazaro D; San-Segundo L; Garayoa M; Garcia-Gomez A; Gutierrez NC; Delgado M; Colado E; Martin-Sanchez J; Lee FY; Ocio EM
Ann Hematol; 2012 Feb; 91(2):257-69. PubMed ID: 21720745
[TBL] [Abstract][Full Text] [Related]
6. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
Maiso P; Ocio EM; Garayoa M; Montero JC; Hofmann F; García-Echeverría C; Zimmermann J; Pandiella A; San Miguel JF
Br J Haematol; 2008 May; 141(4):470-82. PubMed ID: 18341634
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC; Seoane S; Ocaña A; Pandiella A
Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
[TBL] [Abstract][Full Text] [Related]
9. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
10. Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs.
Kumar S; Raje N; Hideshima T; Ishitsuka K; Roccaro A; Shiraishi N; Hamasaki M; Yasui H; Munshi NC; Richardson P; Figg WD; Anderson KC
Leukemia; 2005 Jul; 19(7):1253-61. PubMed ID: 15858615
[TBL] [Abstract][Full Text] [Related]
11. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Lin B; Podar K; Gupta D; Tai YT; Li S; Weller E; Hideshima T; Lentzsch S; Davies F; Li C; Weisberg E; Schlossman RL; Richardson PG; Griffin JD; Wood J; Munshi NC; Anderson KC
Cancer Res; 2002 Sep; 62(17):5019-26. PubMed ID: 12208756
[TBL] [Abstract][Full Text] [Related]
12. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
13. Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells.
Yang M; Huang J; Pan HZ; Jin J
Int J Mol Med; 2008 Oct; 22(4):489-96. PubMed ID: 18813856
[TBL] [Abstract][Full Text] [Related]
14. Small molecule enhancers of rapamycin induce apoptosis in myeloma cells via GSK3A/B preferentially within a protective bone marrow microenvironment.
Nekova TS; Dotterweich J; Schütze N; Einsele H; Stuhler G
Br J Haematol; 2014 Oct; 167(2):272-4. PubMed ID: 24916065
[No Abstract] [Full Text] [Related]
15. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone.
Grigorieva I; Thomas X; Epstein J
Exp Hematol; 1998 Jul; 26(7):597-603. PubMed ID: 9657134
[TBL] [Abstract][Full Text] [Related]
16. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.
Boissy P; Andersen TL; Lund T; Kupisiewicz K; Plesner T; Delaissé JM
Leuk Res; 2008 Nov; 32(11):1661-8. PubMed ID: 18394701
[TBL] [Abstract][Full Text] [Related]
17. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.
Tai YT; Chang BY; Kong SY; Fulciniti M; Yang G; Calle Y; Hu Y; Lin J; Zhao JJ; Cagnetta A; Cea M; Sellitto MA; Zhong MY; Wang Q; Acharya C; Carrasco DR; Buggy JJ; Elias L; Treon SP; Matsui W; Richardson P; Munshi NC; Anderson KC
Blood; 2012 Aug; 120(9):1877-87. PubMed ID: 22689860
[TBL] [Abstract][Full Text] [Related]
18. Using high throughput microtissue culture to study the difference in prostate cancer cell behavior and drug response in 2D and 3D co-cultures.
Mosaad E; Chambers K; Futrega K; Clements J; Doran MR
BMC Cancer; 2018 May; 18(1):592. PubMed ID: 29793440
[TBL] [Abstract][Full Text] [Related]
19. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
Monaghan KA; Khong T; Burns CJ; Spencer A
Leukemia; 2011 Dec; 25(12):1891-9. PubMed ID: 21788946
[TBL] [Abstract][Full Text] [Related]
20. The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
Paíno T; Garcia-Gomez A; González-Méndez L; San-Segundo L; Hernández-García S; López-Iglesias AA; Algarín EM; Martín-Sánchez M; Corbacho D; Ortiz-de-Solorzano C; Corchete LA; Gutiérrez NC; Maetos MV; Garayoa M; Ocio EM
Clin Cancer Res; 2017 Jan; 23(1):225-238. PubMed ID: 27440267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
